Can a Natural Molecule Reduce the Risk of Colitis-Related Cancer?
Chronic inflammatory bowel diseases such as colitis significantly increase the risk of developing colorectal cancer. Persistent inflammation promotes cell transformation and creates an environment conducive to tumor development. Researchers have recently explored the effects of a natural substance called Ardisiacrispin B, extracted from plants used in traditional medicine. Their findings reveal that this molecule could reduce intestinal inflammation and limit the progression of colitis-associated cancer.
In mice suffering from induced colitis and exposed to a carcinogenic agent, Ardisiacrispin B reduced disease symptoms. The treated animals maintained a stable weight, experienced less bleeding, and showed overall improvement in their condition. Examination of their colons revealed a decrease in the number and size of tumors, as well as better preservation of tissue structure. The molecule acts by modulating the composition of the gut microbiota, promoting beneficial bacteria and reducing those associated with inflammation.
Ardisiacrispin B also influences key cellular mechanisms. It decreases the production of inflammatory signals such as interleukin-6 and lipopolysaccharide, which activate signaling pathways involved in tumor growth. Among these pathways, the IL-6/JAK2/STAT3 cascade plays a central role in the transition from chronic inflammation to cancer. By blocking this pathway, as well as others like TLR4/NF-κB, the molecule limits the proliferation of cancer cells and encourages their programmed death.
Researchers observed an increase in markers of apoptosis, the process by which damaged cells self-destruct, while reducing cell proliferation signals. At the same time, Ardisiacrispin B partially restores the balance of the gut microbiota, which is often disrupted in individuals with colitis. An imbalanced microbiota worsens inflammation and promotes tumor development. By enriching populations of protective bacteria, the molecule helps restore a healthier intestinal environment.
These findings suggest that Ardisiacrispin B could offer a preventive and therapeutic approach against inflammation-related colorectal cancer. Its combined action on inflammation, the microbiota, and tumor cell survival makes it a promising candidate for future research. Its use could complement existing treatments by targeting multiple mechanisms at once, without the side effects of conventional therapies.
About Our Sources
Original Publication
DOI: https://doi.org/10.1007/s13659-026-00602-6
Title: Natural triterpenoid Ardisiacrispin B attenuates colitis-associated cancer via JAK2/STAT3 pathway and gut microbiota modulation
Journal: Natural Products and Bioprospecting
Publisher: Springer Science and Business Media LLC
Authors: Hidayat Ullah; Huanli Cui; Yu Li; Binghuang Ye; Weijie Peng; Yongdui Ruan; Weibo Dai; Chunling Ma; Xianjing Hu